Amgen Launches Long-Approved Humira Biosimilar Amjevita

Amgen finally launched Amjevita (adalimumab-atto) in the U.S. yesterday, releasing the first rival to AbbVie’s mega-blockbuster anti-inflammatory drug, Humira.
Source: Drug Industry Daily